• PDF / 169,379 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 27 Downloads / 165 Views

DOWNLOAD

REPORT

---

1 S

Pulmonary embolism and deep vein thrombosis: 4 case reports In an integrated analysis of five randomised phase 3 trials (SELECT-EARLY, SELECT-MONOTHERAPY, SELECTNEXT, SELECTCOMPARE and SELECT-BEYOND), four patients [ages and sexes not stated] were described, who developed pulmonary embolism or deep vein thrombosis during treatment with adalimumab, methotrexate or upadacitinib for rheumatoid arthritis. The patients, who had rheumatoid arthritis, started receiving upadacitinib 30 mg/day (1 patient), adalimumab and methotrexate (1 patient) and methotrexate (2 patients) [routes not stated; not all dosages stated]. Subsequently, the patients developed treatmentrelated events including pulmonary embolism secondary to upadacitinib (1 patient), pulmonary embolism secondary to methotrexate (1 patient), deep vein thrombosis secondary to adalimumab and methotrexate (1 patient), and pulmonary embolism and deep vein thrombosis secondary to methotrexate (1 patient) [duration of treatments to reaction onsets and outcomes not stated]. Choy E, et al. Incidence and risk of venous thromboembolic events among patients with rheumatoid arthritis enrolled in the upadacitinib select clinical trial program. Annals 803519125 of the Rheumatic Diseases 79 (Suppl. 1): 317-318 abstr. THU0195, Jun 2020. Available from: URL: https://ard.bmj.com/content/79/Suppl_1/317 [abstract]

0114-9954/20/1833-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

Reactions 5 Dec 2020 No. 1833